You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 60 No. 1, January 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (141)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Psychopharmacology
 •Public Health
 •Substance Abuse/ Alcoholism
 •Randomized Controlled Trial
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic

Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism

A Double-blind, Placebo-Controlled Study

Falk Kiefer, MD; Holger Jahn, MD; Timo Tarnaske; Hauke Helwig; Peer Briken, MD; Rüdiger Holzbach, MD; Philipp Kämpf, MD; Robert Stracke, MD; Michael Baehr, PhD; Dieter Naber, MD; Klaus Wiedemann, MD

Arch Gen Psychiatry. 2003;60:92-99.

Background  Naltrexone and acamprosate have been shown to be effective in relapse prevention of alcoholism via different pharmacologic mechanisms. Since it remains uncertain whether both substances are equally efficient and whether a combination of both drugs potentiates the efficacy, we conducted the first published controlled study comparing and combining both compounds.

Methods  After detoxification, 160 patients with alcoholism participated in a randomized, double-blind, placebo-controlled protocol. Patients received naltrexone, acamprosate, naltrexone plus acamprosate, or placebo for 12 weeks. Patients were assessed weekly by interview, self-report, questionnaires, and laboratory screening. Time to first drink, time to relapse, and the cumulative abstinence time were the primary outcome measures.

Results  Naltrexone, acamprosate, and the combined medication were significantly more effective than placebo. Comparing the course of nonrelapse rates between naltrexone and acamprosate, the naltrexone group showed a tendency for a better outcome regarding time to first drink and time to relapse. The combined medication was most effective with significantly lower relapse rates than placebo and acamprosate but not naltrexone.

Conclusions  The results of this study support the efficacy of pharmacotherapeutic strategies in the relapse prevention of alcoholism. Naltrexone and acamprosate, especially in combination, considerably enhance the potential of relapse prevention.


From the Department of Psychiatry (Drs Kiefer, Jahn, Briken, Holzbach, Kämpf, Naber, and Wiedemann and Messrs Tarnaske and Helwig) and the Pharmacy (Dr Baehr), University Hospital of Hamburg, and Northern Hospital of Hamburg (Dr Stracke), Hamburg, Germany.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.